{"id":"NCT00328770","sponsor":"University of Alberta","briefTitle":"De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma","officialTitle":"De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects","status":"COMPLETED","phase":"PHASE2","dates":{"start":"1996-12","primaryCompletion":"2006-03","completion":"2006-03","firstPosted":"2006-05-22","resultsPosted":"2012-10-01","lastUpdate":"2013-06-24"},"enrollment":70,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Liver Carcinoma"],"interventions":[{"type":"DRUG","name":"Sirolimus","otherNames":["Rapamune"]}],"arms":[{"label":"Sirolimus based immunosuppression","type":"EXPERIMENTAL"}],"summary":"This study investigates whether sirolimus could decrease the rate of hepatoma recurrence after liver transplantation in high risk hepatoma patients.","primaryOutcome":{"measure":"Percentage of Participants Surviving at One and Four Years After Liver Transplant","timeFrame":"1 & 4 years","effectByArm":[{"arm":"Patient Survival","deltaMin":85,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Canada"]},"refs":{"pmids":["19192962"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":70},"commonTop":["Other unspecified reasons for discontinuation of sirolimus","Mouth ulcers","Dyslipidemia"]}}